James McCloskey

Nov 11, 2024 | onclive.com | James McCloskey |Thomas W. LeBlanc |Thomas Leblanc

OpinionVideoNovember 11, 2024Author(s):,Panelists discuss how community oncologists can apply key takeaways from this clinical scenario in their practice, emphasizing the importance of collaborating with academic clinicians for optimal patient identification and treatment selection in the evolving landscape of lower-risk MDS management. Video content above is prompted by the following:What are some key takeaways you wish to offer community oncologists from this clinical scenario and discussion?

Nov 4, 2024 | onclive.com | James McCloskey |Thomas W. LeBlanc |Thomas Leblanc

OpinionVideoNovember 4, 2024Author(s):,Panelists discuss how the treatment landscape for lower-risk MDS may evolve with emerging novel agents and combination strategies, including studies on luspatercept vs epoetin alfa, luspatercept combinations, elritercept, roxadustat, and canakinumab, potentially offering new options for patients with suboptimal responses to current therapies.

Nov 4, 2024 | onclive.com | James McCloskey |Thomas W. LeBlanc |Thomas Leblanc

OpinionVideoNovember 4, 2024Author(s):,Panelists discuss how imetelstat, a telomerase inhibitor recently approved by the FDA on June 6, 2024, works and its efficacy as demonstrated in the IMerge trial, while highlighting key adverse events that community oncologists should be vigilant about when considering this treatment for patients with lower-risk MDS.

Oct 28, 2024 | onclive.com | James McCloskey |Thomas W. LeBlanc |Thomas Leblanc

OpinionVideoOctober 28, 2024Author(s):,Panelists discuss how their clinical experience with ESA failure rates and timelines compares with reported outcomes in large community practice studies, and how they counsel patients on the choice between luspatercept and ESAs as first-line therapy for lower-risk MDS, incorporating patient preferences and patient-reported outcomes from recent clinical trials.

Oct 28, 2024 | onclive.com | James McCloskey |Thomas W. LeBlanc |Thomas Leblanc

OpinionVideoOctober 28, 2024Author(s):,Panelists discuss how luspatercept’s role in ring sideroblast–negative MDS populations is evolving based on recent clinical trial data, including the COMMANDS trial and PACE-MDS study, with particular attention to the impact ofEPO levels on treatment decisions and outcomes. Video content above is prompted by the following:What is the role of luspatercept in the RS-negative population?